Novavax, Inc. NVAX
9.68 USD +0.15 (+1.57%)
At closeNov 3, 2026, 4:16 PM EST
9.68 0.00 0.00%
After hours · Nov 3, 4:16 PM ET
9.45 Day range 9.95
6.20 52-week range 13.39
- YTD
- +44.05%
- 1 year
- +22.38%
- Market cap
- 1.60B
- Revenue (ttm)
- 413.80M
- Profit margin
- -59.87%
- EPS (ttm)
- -1.58
- Shares out
- 164.95M
- Forward P/E
- -59.06
- YTD return
- +44.05%
- 1-year return
- +22.38%
- Volume
- 3.46M
- Avg volume
- 6.35M
- Open
- 9.56
- Previous close
- 9.53
- Day's range
- 9.45 – 9.95
- 52-week range
- 6.20 – 13.39
- Beta
- 2.72
- Analysts
- Buy
- Price target
- 14.44 (+49.2%)
- Earnings date
- Nov 5, 2026
2Y +0.51 (+5.59%)
Key statistics
- Enterprise value
- 1.15B
- PEG ratio
- 1.32
- Price / sales
- 3.86
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -76.30%
- Free cash flow
- 153.39M
- Total cash
- 719.34M
- Total debt
- 297.32M
- Return on equity
- 0.00%
- Short % of float
- 28.89%
- 50-day average
- 10.47
- 200-day average
- 9.30
Analyst view
Consensus: buy
Buy
Price target (mean) 14.44 +49.2% upside
Now 9.68
- Target (low)
- 7.00
- Target (mean)
- 14.44
- Target (high)
- 25.00
Ratings (0m) 9 5 buy · 1 hold · 3 sell
- Strong buy0
- Buy5
- Hold1
- Sell1
- Strong sell2
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.42.
Financials — quick view
NVAX Revenue — quarterly 56.70M
NVAX Net income — quarterly -53.39M
NVAX EPS — quarterly -0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.34595 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.37984 | -0.32 | +0.06 | +15.75% |
| May 6, 2026 | Mar 31, 2026 | -0.25 | -0.06 | +0.19 | +76.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.66 | 0.11 | +0.77 | +116.67% |
| Nov 6, 2025 | Sep 30, 2025 | -1.08 | -1.25 | -0.17 | -15.74% |
| Aug 6, 2025 | Jun 30, 2025 | -0.07 | 0.62 | +0.69 | +985.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Citigroup | main | Sell | Sell |
| Jun 11, 2026 | BTIG | reit | Buy | Buy |
| May 6, 2026 | TD Cowen | main | Hold | Hold |
| Feb 27, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jan 20, 2026 | BTIG | reit | Buy | Buy |
| Nov 18, 2025 | JP Morgan | main | Underweight | Underweight |
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- novavax.com
News
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release 
Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid 
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe 
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher 
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know 
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know 
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors 
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push 
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened
Your note
Sign in to keep a note on NVAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTON GREGG H | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 47,685 |
| CASEY MARK J | Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 90,067 |
| DOUGLAS RICHARD H | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 73,220 |
| JACOBS JOHN C | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 225,680 |
| KELLY JAMES PATRICK | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 5, 2026 | 130,599 |
| MOTT DAVID M | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 79,770 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.46% | 13,946,881 | 135.01M | Jun 29, 2026 |
| Shah Capital Management | 7.38% | 12,173,481 | 117.84M | Sep 29, 2026 |
| State Street Corporation | 7.12% | 11,740,550 | 113.65M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.61% | 7,607,996 | 73.65M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.40% | 7,257,449 | 70.25M | Jun 29, 2026 |
| Sanofi | 4.17% | 6,880,481 | 66.60M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 5,197,170 | 50.31M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.79% | 4,603,628 | 44.56M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.41% | 3,971,987 | 38.45M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,766,470 | 36.46M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 2,163,104 | 20.94M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 1,893,260 | 18.33M | Jun 29, 2026 |